XyloCor Therapeutics’ lead candidate, a one-time gene therapy dubbed XC001, has met both safety and efficacy goals among 28 patients with refractory angina.
Follow
FierceBiotech
@FierceBiotech
Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at fiercebiotech.questexinfo.com/loading.do?ome
FierceBiotech’s Tweets
XyloCor has shared positive phase 1/2 results for its lead gene therapy, paving the way for pivotal trial
2
2
Walmart, J&J Consumer Health, and health insurer and innovative programmer CareSource come together to make some changes for Black mothers.
1
Amid myriad biotech layoffs, Moderna is staffing up big time, and the company’s new chief technical operations officer figures it's just a start.
4
9
Without specifics, it remains unclear whether Breyanzi will bring meaningful advancement in this indication.
1
2
NICE released a final draft guidance blessing for Gilead's Yescarta for routine use through England’s NHS in certain leukemia patients.
3
3
It’s early days for AC Immune’s Alzheimer’s disease vaccine, but a sneak peak at phase 1b/2 data showed the anti-amyloid beta vaccine elicited a response.
2
Korea-based biotech GenKOre has inked a deal with a U.S. biopharma worth up to $300 million biobucks for developing in vivo gene editing therapies.
2
A weeks-long spat between Sesen Bio leadership and a rival group of investors is boiling over as the two disagree over a planned merger.
2
1
1
Ocuphire Pharma’s diabetic retinopathy candidate missed the primary endpoint of a phase 2 trial, sending the company’s shares down over 25%.
1
1
Weeks after Magenta dropped down a dose level, a patient died after receiving the lower dose, prompting the biotech to voluntarily pause the study.
As an FDA approval decision looms, Sanofi has unveiled more data from a phase 3 trial of its hemophilia A rival to Roche’s blockbuster Hemlibra.
The EMA sent a letter of support for a model-based clinical trial simulation platform to find new treatments for Duchenne muscular dystrophy.
With an oversubscribed fund of $350 million in hand, the new VC Dimension aims to bridge the gap between the present and the future for biotech.
1
After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic.
3
The trio of cofounders behind new VC Dimension believe they're on the precipice of a revolution in biotech and beyond
1
1
1
"Anybody who is not afraid of a lupus study is an idiot, you shouldn’t trust them." — Roivant CEO Matt Gline on the 'vant' company's future.
Quote Tweet
Roivant CEO Matt Gline wants to shed the company's reputation as a discard company as it teases a pivotal year with a handful of critical readouts.
loom.ly/opjWbXo
3
5
Roivant CEO Matt Gline wants to shed the company's reputation as a discard company as it teases a pivotal year with a handful of critical readouts.
1
Executives from BMS, Regeneron, Roche's Genentech and more weighed in on the future of cancer vaccines after recent positive readouts.
2
8
12
Vertex and CRISPR have secured European Medicines Agency validation of the approval application for their CRISPR-Cas9 candidate.
2
3
Cidara overcame the uncertainties raised by the FDA’s advisory committee to receive near-unanimous backing for its antifungal drug.
1
Two years after signing a collab with Takeda, KSQ Therapeutics has garnered interest from another Japanese pharma.
1
Cassava, which has faced questions about the integrity of its Alzheimer’s data, is claiming a phase 2 win—but investors aren’t convinced.
1
An SEC filing released this week gives far greater insight into the dealings that went into the first major M&A deal of 2023 between AstraZeneca and CinCor.
3
Nobel Laureate Jennifer Doudna, Ph.D., predicts a bright future for the tech, complicated by a need for better delivery and high manufacturing costs.
6
6
J&J took the trimmers to the edge of its oncology pipeline, culling a solid tumor and prostate cancer asset, respectively.
1
4
There's a time and a place for everything, and right now might be the time for venture debt as biotechs operate on razor-thin margins.
1
3
The microbiome biotech has decided to stop the study and seek to offload assets in the face of a frosty funding forecast and slow enrollment.
2
3
The class actions accuse the biotech of misrepresenting clinical trial data and failing to enroll patients in a confirmatory phase 3 study.
1
A brutal year for biotech has private investors eyeing bets with less risk and more emphasis on single assets over drug discovery engines.
1
2
The latest phase 2a idiopathic pulmonary fibrosis data drop suggests dialing up the bexotegrast dose boosts efficacy without compromising safety.
1
5
New week, new scoops for .
is laying off 133 employees from its U.S.-based research team in Billerica, MA. The cuts represent a 26% reduction in the Billerica team and an 11% reduction in EMD Serono's Massachusetts base.
1
7
6
Show this thread
Speaking to Morphic this morning, they insisted the ABBV and JNJ partnerships had still been productive
Quote Tweet
Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech.
loom.ly/hATd6PA
1
The biotech layoffs aren't letting up in January. Latest exclusive courtesy of
Quote Tweet
@merckgroup is laying off more than 130 employees from a U.S.-based research wing in Billerica, MA. The cuts represent a 26% reduction in the Billerica team and an 11% cut to the larger U.S. outpost based in Massachusetts. The scoop from @maxonwifi: fiercebiotech.com/biotech/merck-
2
Fifteen months after the FDA blindsided Agenus with a decision not to offer accelerated approval for balstilimab, the biotech is back with fresh data.
1
4
Do you agree with Sarah Emond of ICER that we can have a balance between innovation and fair pricing?
Listen to the full episode here: fiercepharma.com/pharma/top-lin
0:23
587 views
3
3
Insulet has issued an alert for a data breach that may have compromised the health data of thousands of users of its Omnipod Dash insulin pumps.
2
1
Prosecutors cited an instance ahead of Elizabeth Holmes' sentencing last year in which she appeared to be preparing to flee the country.
1
Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech.
2
3